Sensorion's hearing loss drug reaches target in comeback story after phase 2 failure

Sensorion has cleared a hurdle on the comeback trail for its hearing loss candidate. Therapeutic concentrations of the drug were detected in the inner ears of all sampled patients during a midstage test, suggesting the small molecule reaches its target area and setting the stage for the release of hearing data later this year.